Get started
Author

Veronica Murianni

Observed names: Murianni V, Murianni, Veronica, V. Murianni, Veronica MURIANNI
Institution: Ospedale di Sanremo
ORCID: 0000-0002-4955-0295
Observed ORCID: 0000-0002-4955-0295
OpenAlex ID: A5045717411
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
2021 · Matteo Bauckneht, Sara Elena Rebuzzi, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 67
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
2021 · Sara Elena Rebuzzi, Lodovica Zullo, et al. · International Journal of Molecular Sciences · 65
PDF
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 61
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
2022 · S.E. Rebuzzi, A. Signori, et al. · ESMO Open · 47
PDF
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
2020 · Matteo Bauckneht, Sara Elena Rebuzzi, et al. · Cancers · 31
PDF
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
2022 · Sara Elena Rebuzzi, Luigi Cerbone, et al. · Therapeutic Advances in Medical Oncology · 26
PDF
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
2021 · Sara Elena Rebuzzi, Giuseppe Luigi Banna, et al. · Cancers · 18
PDF
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
2022 · Pasquale Rescigno, Marco Maruzzo, et al. · The Oncologist · 17
PDF
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
2022 · Giuseppe Luigi Banna, Umberto Basso, et al. · Current Oncology · 16
PDF
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)
2023 · Alessandra Damassi, Malvina Cremante, et al. · Clinical Genitourinary Cancer · 12
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer
2023 · Malvina Cremante, Silvia Puglisi, et al. · Journal of Oncology Pharmacy Practice · 9
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score
2022 · Giuseppe FORNARINI, Sara E. REBUZZI, et al. · Minerva Urology and Nephrology · 8
Immunotherapy Retreatment: Case Report, Review of the Literature and Proposal for the Definition of Different Scenarios
2021 · Roberto Borea, Alessandra Damassi, et al. · Immunotherapy · 7
Reliability of patient-reported toxicities during adjuvant chemotherapy
2023 · Malvina Cremante, Alessandro Pastorino, et al. · European Journal of Cancer · 5
Durable Response after Immunotherapy Discontinuation for Delayed and Severe Immune-related Adverse Event: A Case Report
2021 · Guido Pesola, Veronica Murianni, et al. · Immunotherapy · 5
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
2026 · Sara Elena Rebuzzi, Aruni Ghose, et al. · The Oncologist · 4
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma
2025 · Veronica Murianni, Marina Campione, et al. · Journal of Geriatric Oncology · 4
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
2024 · Veronica Murianni, Alessio Signori, et al. · Frontiers in Oncology · 4
PDF
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
2023 · Sara Elena Rebuzzi, Matteo Brunelli, et al. · Cancers · 4
PDF
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
2024 · Fabio Catalano, Matteo Brunelli, et al. · Future Oncology · 2
PDF
The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer.
2023 · Annalice Gandini, Valentino Martelli, et al. · Journal of Clinical Oncology · 2
PDF
Combined Response of Advanced Cutaneous Squamous Cell Carcinoma and Renal Cell Carcinoma to Immunotherapy: A Case Report
2022 · Veronica Murianni, Luigi Cerbone, et al. · Immunotherapy · 2
Adherence to oral treatments in elderly patients with advanced prostate cancer: The ADHERE study, a prospective trial of the Meet-URO network.
2022 · Pasquale Rescigno, Marco Maruzzo, et al. · Journal of Clinical Oncology · 2
Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient
2021 · Fabio Catalano, Sara Elena Rebuzzi, et al. · Anti-Cancer Drugs · 2
Response to letter to the editor: “Insights on nivolumab-based immunotherapy and prognostic stratification in older patients with metastatic renal cell carcinoma”
2025 · Veronica Murianni, Giuseppe Luigi Banna · Journal of Geriatric Oncology · 1
Works count: 42
Citation count: 424
H-index: 10
I10-index: 10
Year
Topic
Type